More recently, clinical trials targeting the PD-1/PD-L1 axis with anti-PD1 monoclonal antibodies revealed their safety [98] and achieved promising results, with tumor regressions in patients with advanced cancer [99, 100], thus indicating another possible pathway to be explored in the clinic. Here, CD274 is linked to neoplasm.